Elizabeth Yeu Lin - 14 Sep 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Director
Signature: /s/ Leonard M. Greenstein, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 14 Sep 2022
Net transactions value: +$296,606
Form type: 4
Filing time: 16 Sep 2022, 16:24:45 UTC
Previous filing: 17 Jun 2022
Next filing: 16 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Purchase	$193,001	+12,040		$16.03	12,040	14 Sep 2022	By 401(k) Plan	F1
transaction	TARS	Common Stock	Purchase	$103,604	+6,360		$16.29	6,360	14 Sep 2022	By Spouse's Roth IRA

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.94 to $16.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.94 to $16.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.